Line Plot from Scientific Research

cUHDRS (key secondary endpoint) is presented as LSMean changes from baseline to week 65 for the ITT and mITT populations. LSMean differences between the placebo and pridopidine treatment arms are shown at each time point. Sample sizes at week 65 were: placebo, n = 249 and pridopidine, n = 250 (ITT); and placebo, n = 247 and pridopidine, n = 242 (mITT). All replicates represent biologically independent participants. Statistical analyses were performed using a maximum likelihood-based mixed-effects model for repeated measures (MMRM). Data are presented as LSMean +/- 95% CI.

DOI